Allergy Asthma Immunol Res.  2015 Sep;7(5):419-420. 10.4168/aair.2015.7.5.419.

More Effective Strategies are Needed for Elderly Asthmatics in Real-World Practice

• Song WJ
• Jee YK

• KMID: 2147949
• DOI: http://doi.org/10.4168/aair.2015.7.5.419

Abstract

No abstract available.

MeSH Terms

Aged*
Humans

Reference

1. Yáñez A, Cho SH, Soriano JB, Rosenwasser LJ, Rodrigo GJ, Rabe KF, et al. Asthma in the elderly: what we know and what we have yet to know. World Allergy Organ J. 2014; 7:8.

2. Song WJ, Cho SH. Challenges in the management of asthma in the elderly. Allergy Asthma Immunol Res. 2015; 7:431–439.

3. Ye YM, Kim SH, Hur GY, Kim JH, Park JW, Shim JJ, et al. Addition of montelukast to low-dose inhaled corticosteroid leads to fewer exacerbations in older patients than medium-dose inhaled corticosteroid monotherapy. Allergy Asthma Immunol Res. 2015; 7:440–448.

4. Joos S, Miksch A, Szecsenyi J, Wieseler B, Grouven U, Kaiser T, et al. Montelukast as add-on therapy to inhaled corticosteroids in the treatment of mild to moderate asthma: a systematic review. Thorax. 2008; 63:453–462.

5. FitzGerald JM, Foucart S, Coyle S, Sampalis J, Haine D, Psaradellis E, et al. Montelukast as add-on therapy to inhaled corticosteroids in the management of asthma (the SAS trial). Can Respir J. 2009; 16:Suppl A. 5A–14A.

6. Virchow JC, Mehta A, Ljungblad L, Mitfessel H. MONICA study group. Add-on montelukast in inadequately controlled asthma patients in a 6-month open-label study: the MONtelukast In Chronic Asthma (MONICA) study. Respir Med. 2010; 104:644–651.

7. Korenblat PE, Kemp JP, Scherger JE, Minkwitz MC, Mezzanotte W. Effect of age on response to zafirlukast in patients with asthma in the Accolate Clinical Experience and Pharmacoepidemiology Trial (ACCEPT). Ann Allergy Asthma Immunol. 2000; 84:217–225.

8. Creticos P, Knobil K, Edwards LD, Rickard KA, Dorinsky P. Loss of response to treatment with leukotriene receptor antagonists but not inhaled corticosteroids in patients over 50 years of age. Ann Allergy Asthma Immunol. 2002; 88:401–409.

9. Nyenhuis SM, Schwantes EA, Mathur SK. Characterization of leukotrienes in a pilot study of older asthma subjects. Immun Ageing. 2010; 7:8.

10. Bozek A, Warkocka-Szoltysek B, Filipowska-Gronska A, Jarzab J. Montelukast as an add-on therapy to inhaled corticosteroids in the treatment of severe asthma in elderly patients. J Asthma. 2012; 49:530–534.

11. Hon KL, Leung TF, Leung AK. Clinical effectiveness and safety of montelukast in asthma. What are the conclusions from clinical trials and meta-analyses? Drug Des Devel Ther. 2014; 8:839–850.

12. Price D, Musgrave SD, Shepstone L, Hillyer EV, Sims EJ, Gilbert RF, et al. Leukotriene antagonists as first-line or add-on asthma-controller therapy. N Engl J Med. 2011; 364:1695–1707.

13. Song WJ, Morice AH, Kim MH, Lee SE, Jo EJ, Lee SM, et al. Cough in the elderly population: relationships with multiple comorbidity. PLoS One. 2013; 8:e78081.